Literature DB >> 22315095

Percutaneous nephrostomy versus indwelling ureteral stent in the management of gynecological malignancies.

Yan Song1, Xiang Fei, Yongsheng Song.   

Abstract

OBJECTIVES: The aims of this study were to evaluate the efficacy of retrograde ureteral stenting and to identify the predictive factors for potential failure of this technique in women with advanced gynecologic malignancies.
METHODS: From 2006 to 2010, a retrospective analysis was performed on a total of 75 patients with ureteral obstruction due to gynecologic malignancies. This population was divided into group 1 (n = 50) in which retrograde stent placement was successful, and group 2 (n = 25) in which stent placement failed and subsequent percutaneous nephrostomy tube placement was required. Multivariate analysis was done to identify predictors of the failure of ureteral stent insertion.
RESULTS: Multivariate analysis revealed that mean preprocedureal serum cystanin C greater than 2.5 mg/L and length of the ureteral obstruction greater than 3 cm were significant predictors of stent failure. Neither the causes nor location of obstruction predicted the need for percutaneous nephrostomy (PCN). No statistical significance was detected among the subgroups of patients with different degrees of hydronephrosis. Statistical significant differences were found between the 2 groups in procedural time, average cost, and mean interval of stent/catheter replacement. However, no statistically significant difference was found in the median survival time and overall stent-related or catheter-related complications between the 2 groups.
CONCLUSIONS: Retrograde ureteral stenting is a first-line option for managing ureteral obstruction caused by gynecologic malignancies. However, in cases where the preprocedureal mean serum cystanin C is greater than 2.5 mg/L and the length of the ureteral obstruction segment is greater than 3 cm, these patients may be better served by percutaneous drainage.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22315095     DOI: 10.1097/IGC.0b013e318243b475

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  7 in total

Review 1.  Use of percutaneous nephrostomy and ureteral stenting in management of ureteral obstruction.

Authors:  Linda Hsu; Hanhan Li; Daniel Pucheril; Moritz Hansen; Raymond Littleton; James Peabody; Jesse Sammon
Journal:  World J Nephrol       Date:  2016-03-06

2.  Role of Preoperative Ureteric Stenting in Optimization of Patients with Retroperitoneal Tumors Associated with Obstructive Uropathy.

Authors:  Sunirmal Choudhury; Papiya Biswas; Sayak Roy; Bitan Chatterjee; Makhan Lal Saha
Journal:  Indian J Surg Oncol       Date:  2020-11-18

3.  Antegrade Ureteral Stenting is a Good Alternative for the Retrograde Approach.

Authors:  Rutger W van der Meer; Saskia Weltings; Arian R van Erkel; Hossain Roshani; Henk W Elzevier; Lukas C van Dijk; Hans van Overhagen
Journal:  Curr Urol       Date:  2017-05-30

4.  Comparison of single and tandem ureteral stenting for malignant ureteral obstruction: a prospective study of 104 patients.

Authors:  Kao-Lang Liu; Bo-Ching Lee; Jian-De Ye; Yu-Hsuan Chang; Chin-Chen Chang; Kuo-How Huang; Yuan-Ju Lee; Yeun-Chung Chang
Journal:  Eur Radiol       Date:  2018-07-04       Impact factor: 5.315

Review 5.  [Management of ureteral obstruction : Value of percutaneous nephrostomy and ureteral stents].

Authors:  C Netsch; B Becker; A J Gross
Journal:  Urologe A       Date:  2016-11       Impact factor: 0.639

6.  Antegrade double-J stent placement for the treatment of malignant obstructive uropathy: A retrospective cohort study.

Authors:  Ghassen Tlili; Houssem Ammar; Sonia Dziri; Khaled Ben Ahmed; Waad Farhat; Sofiene Arem; Emir Acacha; Rahul Gupta; Arib Rguez; Mehdi Jaidane
Journal:  Ann Med Surg (Lond)       Date:  2021-08-16

7.  Evaluation of Galdakao-modified Valdivia position in endoscopic management of malignant ureteric obstruction.

Authors:  Ahmed Emam; Mohamed Elmoazen; Mohamed Shabayek; Amr M Zriek; Hany Hamed Gad
Journal:  Int Urol Nephrol       Date:  2022-01-27       Impact factor: 2.370

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.